Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CRADA with NCI to focus on IGF receptors
September 2007
SHARING OPTIONS:

SEATTLEŚSystems Medicine, a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI), has announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The goal of this CRADA is to develop patented products for the treatment of patients with cancer. The specific focus in this case  is on human monoclonal antibodies, peptides, and small molecules that affect signal transduction through the insulin-like growth factor receptor type I (IGF-IR) and the insulin receptor.
Under terms of the CRADA, which is effective for five years beginning July 31, 2007, Systems Medicine will have an exclusive option to elect an exclusive or non-exclusive commercialization license to any inventions developed under the CRADA.
"If successful, CTI would have exclusive rights to negotiate with NIH for a product that targets the ligand that activates the IGF receptor, unlike current approaches to IGF inhibition that target the receptor directly," says Dr. James A. Bianco, president and CEO of Cell Therapeutics. "This is another exciting addition to several early-stage targeted therapies we are evaluating including SRC inhibitors and bisplatinates."
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.